CSL Behring
在场
是其中之一......
CSL 是一家在股票代码 CSL (AU) 下上市的公司。
CSL 在 11 个国家有直接业务。CSL 拥有 17家子公司，其中包括 CSL Behring、CSL Behring APAC 和 CSL Behring Austria。
他们在：
高管
查看带有其 32 名主要高管的组织结构图
CSL Behring 搜索最多的简介
- Paul McKenzie, Chief Executive Officer and Managing Director
- Michael Ruggiero, Senior Vice President, Global Policy, Advocacy &...
- Karen Neave, Senior Vice President, Chief Risk Officer
高管在CSL变化
- Elaine SorgElaine Sorg 将于20249月1作为 Independent Non-Executive Director 加入公司 (新闻发布的2024八月13号).
创建提醒
跟踪 CSL Behring 的高管变动
生物技术
CSL 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
- Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
生物技术 行业的其他推荐联系人
消息
CSL Behring 的最新新闻稿
- Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships
- CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
- Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
- OPTIONS XII IS COMING HOME
- Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
- CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
- On Pandemic Preparedness
- CSL Seqirus and ARS Pharma sign agreement to commercialise neffy™ (adrenaline nasal spray) in Australia and New Zealand
- View more press releases Close
关于 CSL Behring 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Paul McKenzie 
